The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global radiodermatitis market was valued at US$ 464.4 Million in 2021.
We expect the global radiodermatitis market to exhibit a CAGR of 3.60% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective radiodermatitis treatments to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals.
The rising demand for radiodermatitis treatment to reduce discomfort, minimize pain, and prevent interruption in ongoing radiation therapy, which is used to treat cancer, is primarily driving the global radiodermatitis market.
Based on the product, the global radiodermatitis market has been segmented into topical, oral, and dressings. Currently, topical holds the majority of the total market share.
Based on the distribution channel, the global radiodermatitis market can be divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, retail pharmacy exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.
Some of the major players in the global radiodermatitis market include 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB, and Stratpharma AG.
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at